Loading clinical trials...
Loading clinical trials...
A Phase I/II Study of Immunotherapy With hLL1-DOX in Patients With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
Conditions
Interventions
hLL1-DOX (IMMU-115)
Locations
6
United States
Helen F. Graham Cancer Center
Newark, Delaware, United States
MD Anderson Cancer Center Orlando
Orlando, Florida, United States
IU Health Goshen Center for Cancer Care
Goshen, Indiana, United States
UMass Memorial Cancer Center of Excellence
Worcester, Massachusetts, United States
John Theurer Cancer Center Hackensack University Medical Center
Hackensack, New Jersey, United States
U.T. MD Anderson Cancer Center Houston
Houston, Texas, United States
Start Date
August 1, 2012
Primary Completion Date
November 1, 2016
Completion Date
October 1, 2017
Last Updated
October 8, 2021
NCT06846671
NCT07218341
NCT05735717
NCT07030400
NCT05006716
NCT07277231
Lead Sponsor
Gilead Sciences
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions